logo-loader
viewMicro Focus International plc

Micro Focus continues to expect moderation in revenue decline from continuing business in current year

The group said its guidance continues to be for a revenue decline of between 4% and 6% for its MFPP business in the year ended 31 October 2019, compared to a 7.1% drop in the year earlier

Micro Focus office
For the 12 months to 31 October 2018, Micro Focus reported that revenue fell to US$3.68bn

Micro Focus International PLC (LON:MCRO) has said it continues to expect a moderation in the decline of its revenue from its continuing business in the current year.

In a brief statement ahead of its annual general meeting today, the FTSE 100-listed enterprise software company said its guidance continues to be for a revenue decline of between 4% and 6% for its MFPP business in the year ended 31 October 2019, compared to a 7.1% drop the year earlier.

READ: Micro Focus jumps on share buyback extension as it moves on from disruptive HPE integration

For the 12 months to 31 October 2018, Micro Focus reported a fall in revenue to US$3.68bn.

The company said it will release its results for the six months to 30 April 2019 on July 9.

In early morning trading, Micro Focus shares were 0.6% lower at 1,977p.

 

 

Quick facts: Micro Focus International plc

Price: 1102.8 GBX

LSE:MCRO
Market: LSE
Market Cap: £3.68 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 35 minutes ago

RNS

Total Voting Rights

1 week, 1 day ago

Notification of major holdings

1 week, 5 days ago

Trading update

2 weeks, 6 days ago

Director Declaration

3 weeks, 1 day ago

Total Voting Rights

on 1/11/19

2 min read